(NU/1433-33) GitLife Biotech: providing a lab-in-the-cloud versioning control system for engineered cell lines. Commercialisation of university research through provision of management skills to assist in successful spin-out company creation and scale-up
What the buyer wrote
Professor Krasnogor saw an opportunity in developing a solution to the “Integration” problem that is generic for biotechnology and the life sciences beyond the specifics of these two projects. This is how the idea of establishing GitLife Biotech and the development of the CellRepo technology, as a versioning control system for engineered cell lines, including biotechnology microorganisms, in the cloud was born. The plan is to spin out GitLife Biotech Ltd in Q3 2022. To be able to spin out and take forward this opportunity, securing the involvement of experienced and appropriate business leadership is both essential and complementary to the existing technical staff and resource. Commercial an…
Bid for this and lost? There is a short window in which the decision can be questioned.
Awarded to
Details
- What the buyer calls it
- (NU/1433-33) GitLife Biotech: providing a lab-in-the-cloud versioning control system for engineered cell lines. Commercialisation of university research through provision of management skills to assist in successful spin-out company creation and scale-up
- How they are buying
- Advertised, shortlist firstSuppliers applied to be considered, and the buyer picked who went on to bid.
- Type
- services
- Dynamic market
- Yes: you can apply to join at any time. How these work
- Where
- in the North East
- Kind of work
- Professional services
Who the buyer named
The buyer published a contact address on this notice.